RxDoctor Payments Data

Jennifer Goodin, APRN

Family · Dayton, OHNPI 1215687199

Payments from drug & device makers

$6,735in general payments, 2019–2025

Across 413 payments — averaging $16.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • GSK$619
  • Lilly USA, LLC$536
  • AstraZeneca$442
  • Novo Nordisk$442
  • Corcept Therapeutics$436
  • plus $3K from 29 others

What the payments were for

  • Food & beverage$6,735100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,735 in reported general payments places this provider in the 95th percentile of 6,812 family providers in Ohio.

See all family providers in Ohio

Medicare billing

Part B allowed, 2024
$31,749
Medicare patients
127
Services billed
1,100

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin37$45,889
OzempicSemaglutide31$39,230
JanuviaSitagliptin Phosphate26$36,609
MounjaroTirzepatide24$35,741
EliquisApixaban29$31,264
TrulicityDulaglutide22$28,727
FarxigaDapagliflozin Propanediol20$22,405
Trelegy ElliptaFluticasone/Umeclidin/Vilanter20$17,231
Breztri AerosphereBudesonide/Glycopyr/Formoterol18$11,714
Lantus SolostarInsulin Glargine,hum.Rec.Anlog54$7,031
Gabapentin122$2,881
Donepezil Hcl54$2,829
Humalog Kwikpen U-100Insulin Lispro20$2,818
Atorvastatin Calcium196$2,042
Pantoprazole Sodium111$1,550

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$536$64,46746 claims
Boehringer IngelheimJardiance$171$45,88937 claims
Novo NordiskOzempic$442$39,23031 claims
MerckJanuvia$34$36,60926 claims
AstraZenecaFarxiga, Breztri Aerosphere$442$34,11938 claims
PfizerEliquis$390$31,26429 claims
GSKTrelegy Ellipta$619$17,23120 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 6,812 family providers in Ohio.

Other family in Dayton

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →